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STUDY PROTOCOL Open Access
Reducing inappropriate psychotropic drug
use in nursing home residents with
dementia: protocol for participatory action
research in a stepped-wedge cluster
randomized trial
Claudia M. Groot Kormelinck1* , Charlotte F. van Teunenbroek1, Boudewijn J. Kollen1, Margreet Reitsma2,
Debby L. Gerritsen3, Martin Smalbrugge4 and Sytse U. Zuidema1
Abstract
Background: Psychotropic drugs are often prescribed to treat neuropsychiatric symptoms in nursing home
residents with dementia, despite having limited efficacy and considerable side effects. To reduce the inappropriate
prescribing of these psychotropic drugs, various non-pharmacological, psychosocial, person-centered, or
multidisciplinary interventions are advocated. However, existing multidisciplinary interventions have shown variable
effects, with limited effectiveness often resulting from suboptimal implementation. We hypothesize that an effective
intervention needs to fit the local situation of a nursing home and that support should be offered during
implementation.
Methods: We will embed participatory action research within a stepped-wedge cluster randomized controlled trial
to study the effects of a tailored intervention and implementation plan to reduce inappropriate psychotropic drug
prescribing. Nursing homes will be provided with tailored information about the perceived problems of managing
neuropsychiatric symptoms and we will offer coaching support throughout. Alongside the participatory action
research, we will perform a process evaluation to examine the quality of the study, the intervention, and the
implementation. Our aim is to recruit 600 residents from 16 nursing homes throughout the Netherlands, with
measurements taken at baseline, 8 months, and 16 months. Nursing homes will be randomly allocated to an
intervention or a deferred intervention group. During each intervention stage, we will provide information about
inappropriate psychotropic drug prescribing, neuropsychiatric symptoms, and difficulties in managing
neuropsychiatric symptoms through collaboration with each nursing home. After this, a tailored intervention and
implementation plan will be written and implemented, guided by a coach. The primary outcome will be the
reduction of inappropriate prescribing, as measured by the Appropriate Psychotropic drug use In Dementia index.
Secondary outcomes will be the frequency of psychotropic drug use and neuropsychiatric symptoms, plus quality
of life. A mixed methods design will be used for the process evaluation. Effects will be assessed using multilevel
analyses. The project leader of the nursing home and the coach will complete questionnaires and in-depth
interviews.
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Discussion: We anticipate that the proposed tailored intervention with coaching will reduce inappropriate
psychotropic drug prescribing for nursing home residents with neuropsychiatric symptoms. This study should also
provide insights into the barriers to, and facilitators of, implementation.
Trial registration: NTR5872, registered on July 2, 2016.
Keywords: Inappropriate psychotropic drug use, Dementia, Nursing home, Neuropsychiatric symptoms,
Implementation, Psychosocial interventions
Background
Dutch nursing homes (NHs) accommodate approxi-
mately 50,000 residents with dementia [1], and in these,
the prevalence of neuropsychiatric symptoms (NPS) is
high. A systematic review, for example, indicated that
82% of residents exhibited at least one NPS, with agita-
tion and apathy being most prevalent [2]. These symp-
toms affect both the quality of life (QoL) of residents [3]
and the health of nursing staff [4].
NPS in dementia is typically treated with psycho-
tropic drugs, including antipsychotics, hypnotics or sed-
atives, anxiolytics, antidepressants, anticonvulsants, and
anti-dementia drugs [5–8]. Despite the frequency with
which these are prescribed, there is evidence that such
drugs have limited effect on NPS in residents with de-
mentia [9, 10] especially when used in the long-term
[11]. These psychotropic drugs are also associated with
significant side effects. Antipsychotics are known to in-
crease the risk of stroke and mortality [6, 12] and to
cause extrapyramidal symptoms and drowsiness [13].
The use of sedatives, hypnotics, antidepressants, and
benzodiazepines is also associated with falls [14].
Together, these side effects can negatively affect QoL
[10, 15–17]. Although guidelines recommend that the
use of psychotropic drugs be restricted in the treatment
of NPS in dementia, and although non-pharmacological
alternatives are recommended for first-line treatment
[18], psychotropic drugs are often prescribed in
Western Europe, with antipsychotics and antidepres-
sants being used with the greatest frequency [19].
Indeed, despite the existence of these guidelines, psy-
chotropic drug prescribing has not substantially de-
creased in the Netherlands, with 60% of Dutch NH
residents with dementia and NPS being prescribed at
least one of these agents [20]. In addition, there is evi-
dence that psychotropic drugs are frequently prescribed
in the long-term, which again runs contrary to the
guideline recommendations [21–23]. Research suggests
that only 10% of psychotropic drug prescriptions for
NPS are fully appropriate for residents with dementia,
in terms of indication, evaluation, dosage, drug-drug in-
teractions, drug-disease interactions, duplications, and
therapy duration [20].
Several studies provide insights into the factors associ-
ated with the psychotropic drug prescribing. Relevant fac-
tors include physician and nurse attitudes to NPS and
psychotropic drugs [6, 24, 25], knowledge or experience of
NPS, the interpersonal skills of nurses, knowledge of the
effectiveness and side effects of psychotropic drugs, com-
munication or cooperation between professionals and
with family [24], and external factors (e.g., staffing, the
NH setting, and local policies) [24, 25]. However, these
can only be challenged if effective non-pharmacological
interventions are available, including person-centered and
multidisciplinary interventions. Person-centered interven-
tions focus on behavior, emotion, stimulation, or cogni-
tion (e.g., reminiscence, validation, music therapy, sensory
stimulation) [26], whereas multidisciplinary interventions
for NH staff focus on education, in-reach services, medica-
tion reviews, or multicomponent interventions to reduce
inappropriate prescribing [27].
In recent decades, a number of multidisciplinary care
programs have been developed to target the factors as-
sociated with inappropriate prescribing and/or to shift
practice toward a greater use of non-pharmacological
interventions (e.g., STA-OP, GRIP, PROPER, AiD, De-
mentia Care Mapping, RedUSe, and TIME) [28–34].
RedUSe is a good example of a multi-strategic interdis-
ciplinary intervention that took place in 150 residential
aged care facilities and was shown to reduce anti-
psychotic prescribing by 13% and benzodiazepine pre-
scribing by 21%, without increasing their pro re nata
use. Although this showed that such an intervention
can be successful [34], it is generally the case that the
effects of these multidisciplinary care programs or in-
terventions are variable. In the GRIP study, for ex-
ample, the effects of a multidisciplinary care program
for challenging behavior were considered small, prob-
ably due to suboptimal implementation. Adjusted ana-
lyses showed larger effects in Dementia Specialized
Care Units (DSCUs), in which implementation was
good [29]. The results of a successful and widely imple-
mented person-centered care approach in the United
Kingdom have not been replicated in German NHs
[35]. Although several changes were made to the inter-
vention, it was thought that implementation barriers
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caused the loss of effect between populations. In other
research, Grimshaw et al. stated that implementation
studies seeking to change professional behavior achieve
an effect size of 10 to 20%, with the effects likely related
to the degree to which underlying barriers are ad-
dressed [36]. Striving for any culture change is challen-
ging and takes time, and it might be unrealistic to
expect larger effects. However, it is documented that a
lack of effect may reflect a failure of implementation ra-
ther than a failure of the intervention itself [37, 38].
It appears that several preconditions are required for suc-
cessful implementation of a new intervention, and the ab-
sence of these can effectively block implementation.
Common barriers to implementation in terms of an organi-
zation’s culture have been reported to be the attitude to
change and the support of key persons. Staff turnover,
experience of concurrent and former projects, and
organizational change have also been considered important
organizational barriers [39]. By contrast, organizational pre-
conditions for implementation are the presence of well-
functioning networks, flexible organizational structures, a
dementia-friendly culture, and positive attitudes of involved
staff [32].
As one might imagine, creating a change in NH
practice can be challenging given the complex nature
of these institutions. Consequently, standardized inter-
ventions are less likely to be successful, with a need to
emphasize the specific organizational features of a NH
and their culture to better adapt to their specific needs
[27, 32, 38, 39]. A prerequisite for successful imple-
mentation of any psychosocial intervention, whether
person-centered or multidisciplinary, must therefore
be that it includes some degree of tailoring. On the
one hand, a person-centered intervention needs to be
tailored to the preferences and abilities of a given resi-
dent [40], whereas on the other hand, a multidisciplin-
ary program should consider the specific features of
the organization and whether it fits with the needs, re-
sources, and conditions of the NH at which it is to be
implemented [32, 39]. In addition, as the complexity
of an intervention increases, so too do the demands of
implementation (e.g., GRIP involves multiple interact-
ing components and requires behavioral changes in
both caregivers and recipients). Complexity also varies
with the possible outcomes, the number of individuals
involved, and as stated, the degree to which an inter-
vention is tailored [38]. Due to these challenges, stud-
ies of complex interventions tend to show only small
to modest outcome effects [28, 29, 32, 41].
Designing interventional trials that have enough flexi-
bility to be meaningful and successful in a local setting,
without compromising generalizability, has proved chal-
lenging. In an effort to tackle this issue, Leykum et al.
(2009) explored the integration of participatory action
research (PAR) with a randomized controlled trial (RCT)
design, successfully accounting for the local differences
while creating a framework that allowed for a degree of
generalizability [41]. In PAR, researchers and partici-
pants work collaboratively to define a problem, identify
unmet needs, explore and implement potential solutions,
and evaluate the efficacy of the implemented actions
[42]. PAR aims not only to improve work practices but
also to learn from the implementation process itself,
helping to understand how successful implementation
can be achieved. This allows the knowledge that is
gained to be used to implement future complex care
programs or interventions that focus on both the con-
tent and processes of the intervention. Consequently,
PAR allows complex interventions to be implemented,
supported by knowledge about the local NH context.
According to Leykum et al. (2009), group facilitation, re-
lationship building, and reflection should be addressed
to encourage the incorporation of local conditions and
contexts.
In our study, we will integrate PAR with a stepped-
wedge cluster RCT to create a PAR-RCT study design.
This approach will help us to account for local differ-
ences by adapting to local needs, to use a tailored ap-
proach to improve local practice, and to create a
framework that allows for a degree of generalizability. A
cyclic approach of planning, acting, observing, and
reflecting will be used [42]. We specifically plan to ad-
dress two strategies that we assume will increase the in-
tervention’s effectiveness. First, we will provide NHs
with tailored information about their perceived problems
in managing NPS, including psychotropic drug use, to
obtain a match between the problems experienced by
NHs and the interventions to be implemented. Second,
we will provide NHs with coaching to facilitate imple-
mentation. The coach will help to draft and implement
the intervention plan, paying close attention to the local
context of the NH. This will require dealing with any
initial skepticism about non-pharmacological approaches
or NH staff concerns in an effort to engender the com-
mitment to change and the active engagement of staff
that are essential for successful implementation [40].
We aim to study the effectiveness of implementing a
tailored intervention to reduce inappropriate psycho-
tropic drug prescribing in a PAR-RCT. Our goal is to
change work practices, processes, and cultures at the
level of DSCUs in NHs because these changes tend to
have longer lasting effects [43]. Therefore, interventions
chosen by the NH staff will not directly target residents,
but will instead target medication reviews, behavioral
visits, or the provision of information on residents’ life
stories. We expect that these psychosocial interventions
targeting NH staff can enhance the quality of profes-
sional conduct in NH practice, with positive effects for
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residents. For example, a systematic review demon-
strated that studies reporting on cultural change and in-
volving physicians may lead to a substantial reduction of
antipsychotic drug prescribing [43]. It is anticipated that
our intervention will lead to reductions in inappropriate
psychotropic drug prescribing, the frequency of psycho-
tropic drug use, and the frequency of NPS, as well as to
an improvement in residents’ QoL. Parallel to the PAR-
RCT, a comprehensive process evaluation will be con-
ducted to provide insights into the contribution of the
intervention to practice and to identify any barriers to,
or facilitators of, implementation.
Methods/design
Design and eligibility
We will use a two-armed cluster RCT with a stepped-
wedge design to allow each NH to participate in the
intervention phase and to increase the study’s power
(Fig. 1). We expected that recruitment to a classic RCT
design would be problematic because half do not receive
the intervention, which can be off-putting. A waiting list
procedure would also require including more NHs, and
we want to avoid this because of the resource-intensive
design in terms of time, dedication, and money. In
addition to allowing for smaller sample sizes, other
advantages of stepped-wedge designs are the possibility
to compare both between- and within-cluster effects, as
well as the ability to model effects over time [44].
The study duration will be 16 months, split into two 8-
month periods. Based on a pilot study, we estimated that
the problem analysis for PAR-RCT would take about 2
months. We plan to allow 6months to implement the
chosen interventions because a longer period may lead
to a loss of enthusiasm among NH staff, and because we
anticipate high turnover rates among residents [5] and
staff [32, 39]. The coaching will also be time and cost in-
tensive, and the amount of data collected will require a
huge investment from research assistants and NH staff.
Although we believe that 8 months will be optimal for
these reasons, we do recognize that it might be insuffi-
cient to bring about a change in NH practice. Therefore,
we plan to use the stepped-wedge design to compare the
8 month intervention with a 16 month extended inter-
vention that will allow us to study possible long-term ef-
fects. Using a computer program, 16 NHs will be
randomized by fixed-block randomization into an inter-
vention group or a deferred intervention group (8 NHs
each). In Period 1, the intervention group (Fig. 1, green
blocks) will start by implementing the PAR method,
while the deferred intervention group will start with care
Fig. 1 RID study design. The randomization of nursing homes into start or deferred intervention groups. Abbreviation: RID, Reducing Inappropriate
psychotropic Drug use
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as usual. After 8 months, Period 2 will start, and the de-
ferred intervention group will start the intervention and
the original intervention group will complete a second
intervention phase.
The primary outcome will be the reduction of in-
appropriate psychotropic drug prescribing based on data
collected at baseline, 8 months, and 16months. The stat-
istician will be blinded to the cluster randomization
process, and the NH staff and researchers will be aware
of their participation group by design. Given that we aim
to intervene at the DSCU level and that residents are
not directly subject to an intervention, we have no dis-
continuing criteria, trial stopping rules, or modifying
allocations.
Study population and recruitment
NHs will be recruited by organizing a national kick-off
and using media channels to gain attention. Any inter-
ested NHs in the Netherlands can apply to participate
and will be considered eligible if the board of directors
and the client council agree to participate and are pre-
pared to invest the requisite time. We will exclude NHs
in which major organizational changes are expected dur-
ing the study period or if other projects related to psy-
chotropic drug use are currently running.
The study population will comprise residents with de-
mentia who reside in psychogeriatric units (e.g., DSCUs).
NHs can have several DSCUs, and several DSCUs from
one NH can participate. However, DSCUs designed to
deliver care for residents with Korsakov syndrome, ac-
quired brain injury, Down syndrome, or young-onset de-
mentia will be excluded. Although interventions will be
aimed at the DSCU level, we will still need to gather
data on residents to assess outcomes. Residents will be
eligible to participate if they have a diagnosis of demen-
tia according to the Diagnostic and Statistical Manual of
Mental Disorders (fifth edition), have a life expectancy
of at least 3 months, as judged by a physician, and pro-
vide written informed consent. We will also include
users and nonusers of psychotropic drugs. It is antici-
pated that most residents will be at an advanced stage of
dementia and may be mentally incompetent. The phys-
ician of the relevant DSCU will therefore be asked to as-
sess a resident’s mental competence to provide informed
consent. If they are not deemed competent, an employer
of the registry office at each NH will send the informed
consent form to a residents’ legal representative. In the
absence of a response, a reminder request to return the
informed consent form will be made once. If no re-
sponse will be obtained, residents will not be included.
The PAR-RCT study
The PAR-RCT element will involve a cyclic approach of
planning, acting, observing, and reflecting (Fig. 2) [42].
Half of the NHs will complete two cycles (i.e., those in
the starting intervention group) and the other half of the
NHs will complete one cycle (i.e., the deferred interven-
tion group). Each NH will initially form a multidisciplin-
ary project team (MPT) that will include, as a minimum,
an internal project leader, a nursing staff representative,
a psychologist, and a physician. An external coach will
also participate in the MPT to facilitate the whole
process.
The action research cycle will start with the re-
searchers carrying out a problem assessment. We will
start with the observation phase because effective inter-
ventions should meet the needs identified by staff [45].
This assessment will focus on current daily practice and
difficulties managing NPS, including inappropriate psy-
chotropic drug use, and the results will be presented to
the MPT. Next, the MPT and the coach will reflect on
these results. In this reflection phase, opportunities for
Fig. 2 Cyclic approach of the PAR-RCT. Period 1 is shown in black and Period 2 is shown in gray. Abbreviations, PAR, Participatory action research;
RCT, Randomized Controlled Trial
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improvement will be identified before the MPT moves
on to formulate goals to tackle the identified problems.
Two expected outcomes are predicted. First, a problem
analysis may reveal that the evaluation of psychotropic
drugs is inappropriate. In this instance, NHs may opt to
pursue a clear work policy between physicians, to clarify
the evaluation of psychotropic drugs, or to do medica-
tion reviews more frequently. Second, early detection of
NPS may be identified as a problem. In this instance,
they may recommend e-learning on NPS or implement-
ing the routine use of the Neuropsychiatric Inventory-
Nursing Home version (NPI-NH) by nurses for monitor-
ing. How an NH intervenes will be decided by the coach
and the MPT, with only indirect input from the re-
searchers. The identified goals will be converted into an
intervention and implementation plan. The coach will
support this process and the researchers will assess
whether the plan aims to reduce inappropriate psycho-
tropic drug use. In summary, the information gained
during the problem assessment will be used to formulate
and operationalize the goals for the intervention and im-
plementation plan (planning phase), after which NHs
will implement the interventions (action phase).
NHs will be provided with a toolkit that contains sev-
eral multidisciplinary care programs, such as GRIP or
PROPER, as well as person-centered psychosocial inter-
ventions. The toolkit is a bundle of existing evidence
and practices from which NHs can draw. They will be
free to implement any intervention, either from the tool-
kit or elsewhere, provided the selected interventions
match the problems identified in managing NPS and
psychotropic drug use. Table 1 provides an overview of
the toolkit’s content. In contrast to traditional PAR, the
primary outcome (reduction of inappropriate prescribing
of psychotropic drugs) is fixed in our study.
During the implementation phase, the MPT will have
regular meetings with the coach to monitor progress (ob-
servation phase). At 8months, NHs that start in the inter-
vention group will receive feedback on the level of
inappropriate psychotropic drug prescribing. The results
of this interim analysis should allow them to reflect on
changes in inappropriate prescribing (reflection phase),
making it possible to adapt the intervention and imple-
mentation plan (planning phase), and act accordingly (ac-
tion phase). When there is little or no reduction in the
rate of inappropriate prescribing of psychotropic drugs,
the MPT will be guided to consider choosing different in-
terventions, changing their implementation strategy, or in-
creasing the effort put into implementation.
Coaches will be responsible for the following aspects:
(1) advising and supervising the internal project leader
and the MPT; (2) being present at meetings of the MPT;
(3) advising on the logistical aspects of the research and
improvement process in the organization, including
problem analysis, planning, multidisciplinary embedding,
and sustainability; (4) offering substantive knowledge
about psychotropic drugs, inappropriate prescribing, and
reducing psychotropic drug use; (5) supporting the
organization to get set up; (6) providing access to tools,
methodologies, and learning networks; and (7) advising
on quality assurance and dissemination of the results.
We plan to recruit eight coaches through the Vilans
Center of Expertise for Long-term Care, who in turn,
will source them internally or through cooperating
Table 1 Overview of the eight themes in the toolkit, including examples
1. Leaflets, tips, and explanations - Collection of stories: A pill against yelling
2. Training courses managing NPS - Alzheimer Experience a
- E-learning dementia
3. Videos about psychotropic drugs - Parodies on psychotropic drug use
4. Finding alternatives - 85 practical alternatives to restraint
- The memory suitcase b
5. Methods for NPS and depression - GRIP c
- STA-OP d
- Act in case of depression care program
6. Improving prescription policy - PROPER: structured medication review
- Guideline problem behavior
7. Involving residents and relatives - Digital workbook: tools and materials to
improve contact and cooperation between
client, caregivers, and family
8. Research, articles, publications - Dissertation GRIP study
- Many articles, guidelines
aFilm in which the viewer experiences what dementia entails from different perspectives
bNostalgic suitcases full of memories and music, possibly with animation
cMultidisciplinary care program for managing challenging behavior
dStepped care protocol for the assessment and management of pain and challenging behavior
Abbreviations: GRIP (study) Grip on challenging behavior, NPS Neuropsychiatric symptoms, PROPER PRescription Optimization of Psychotropic drugs in Elderly
nuRsing home patients with dementia, STA-OP (study) serial trial intervention for pain and challenging behavior in advanced dementia patients
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partners. The coaches must be knowledgeable about de-
mentia and have previous consultation expertise in nurs-
ing home organizations.
Each coach will support two NHs. They may spend an
average of 3 h per week with an NH over each 8-month
intervention period. The 8 NHs that start in the intervention
group and have an extended intervention duration will only
receive coaching in the first 8months, which will end after
discussing the interim results. It is expected that time-
intensive weeks will be compensated for by weeks in which
little to no input is needed. Coaches will not be required to
use all allocated hours, and the actual time spent with each
NH is to be determined in consultation with the relevant
MPT. The coaches will be asked to keep a logbook in which
they will be asked to write down the number of hours spent
on coaching, any agreements made with the NH, and other
findings they consider relevant. They will also participate in
monthly supervision sessions, led by a trainer at Utrecht
University. The aim of these sessions is to discuss any diffi-
culties experienced, to find suitable solutions, and for coa-
ches to exchange tips. The extent to which a coach succeed
will be addressed in the process evaluation.
Process evaluation
It is essential for credibility that researchers acquire in-
formation about the quality of an intervention and its
implementation in a given study [46, 47]. Leontjevas
et al. (2012) proposed a process evaluation model based
on first- and second-order data, which we will adopt in
this study. The first-order data provide information
about the internal and external validity, comprising of
the sample quality (e.g., recruitment, randomization, and
reach) and the intervention quality (e.g., relevance, feasi-
bility, and extent to which an intervention was per-
formed). The second-order data are then examined
(implementation knowledge), such as implementation
components that were delivered and received and the
barriers to, and facilitators of, implementation. The in-
ternal project leader and coach will each receive a digital
questionnaire to assess these aspects. We will follow this
up with a semi-structured telephone interview to address
ambiguities and to seek additional comments.
Measurements
An overview of the outcomes and measurement instruments
is provided in Table 2. Demographic data will be extracted
from medical files by the researchers, including residents’
age, sex, type of dementia, pro re nata psychotropic drug
use, date of last medication review, and date of admission to
the DSCU. Cognitive abilities will be examined using the
Cognitive Performance Scale (CPS), a reliable and valid scale
that rates cognition, communication, activities of daily living
Table 2 Overview of the measurement instruments
Variable Measurement instrument Outcome measure Problem analysis/ feedback
MPT
Inappropriate psychotropic drug use APID Primary outcome Problem analysis + feedback
8 and 16months a
Frequency psychotropic drug use Retrieval from medical records Secondary
outcome
Problem analysis + feedback









Current difficulties managing NPS; NH staff Self-designed questionnaire [digital] +
semi-structured interviews for NH staff
– Problem analysis





Attitude toward new interventions EBPAS [digital] c Process evaluation Problem analysis
Organizational culture Questionnaire [digital] CVF scale for
long-term care c
Process evaluation Problem analysis
Process evaluation data model of Leontjevas et al., 2012 Self-designed questionnaire [digital] +
semi-structured interview internal
project leader and coach
Process evaluation –
aNHs who start as an intervention group receive information on psychotropic drug use at the beginning (problem assessment), 8 months (interim results) and 16
months. NHs who start as a deferred intervention group receive information on psychotropic drug use at 8- (problem assessment) and 16months
bEQ-VAS is administered to both nursing staff and relatives, at each measurement (0, 8, 16 months)
cThe EBPAS + organization culture questionnaires are administered in the context of the problem assessment at 0 months (start intervention group) or 8 months
(start deferred intervention group), as well as at 16months in the context of the process evaluation
Abbreviations: APID Appropriateness of Psychotropic Prescription In Dementia, CMAI Cohen–Mansfield Agitation Inventory, CPS Cognitive Performance Scale, CVF
Competing Values Framework, EBPAS Evidence-Based Practice Attitude Scale, MPT Multidisciplinary project team, NPS neuropsychiatric symptoms, NH Nursing
homes, NPI-NH Neuropsychiatric Inventory-Nursing Home, QoL Quality of Life, RISE Revised Index of Social Engagement, VAS Visual analog scale
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and consciousness from 0 (intact) to 6 (very severe impair-
ment) [48]. The instrument has a sensitivity and specificity
of 0.94 and has been validated against the Mini Mental State
Examination [49]. The CPS will be used by nursing staff, on
paper, in the presence of a researcher.
Primary outcome
Psychotropic drugs will be categorized according to the
Anatomical Therapeutic Chemical (ATC) classification
[50]. The primary outcome is the appropriateness of psy-
chotropic drug use, and this will be measured with the
Appropriateness of Psychotropic drug use In Dementia
(APID) index [23]. This index rates the prescription of
regular psychotropic drugs for NPS in people with de-
mentia, including antipsychotic, anxiolytic, hypnotic,
antidepressant, anticonvulsant, and anti-dementia drugs.
Psychotropic drugs administered for dementia, sleep dis-
turbance, and delirium will be scored with the APID
index, but those prescribed for psychiatric disorders will
not be scored. Treatment appropriateness will be mea-
sured on seven domains: indication, evaluation, dosage,
drug-drug interactions, drug-disease interactions, dupli-
cations, and therapy duration. For each domain, a score
between zero (appropriate) and two (inappropriate) can
be given, allowing an overall appropriateness score to be
calculated (weighted sum score). The APID has been
validated in residents of DSCUs in the Netherlands
(intraclass correlation coefficient, 0.577–1.000) [23]. The
researchers will extract information on psychotropic
drug prescribing from medical records.
Secondary outcomes
The secondary outcomes will be the frequency of psy-
chotropic drug use, the frequency of NPS, and the QoL.
The frequency of psychotropic drug use will be extracted
by the researchers from medical files, and NPS and QoL
will be assessed by nursing staff on paper, in the pres-
ence of a researcher. Proxy measures of NPS and QoL
(nurse assessments) will be used on the assumption that
residents lack capacity. NPS will be measured with the
NPI-NH and the Cohen–Mansfield Agitation Inventory
(CMAI). QoL will be measured using the visual analog
scale (VAS) of the EQ. 5D (i.e., the EQ-VAS).
The NPI-NH measures the prevalence, frequency, sever-
ity, and associated caregiver distress of 12 neuropsychi-
atric symptoms. All symptoms are rated on Likert-type
scales, with four-point scales used for frequency, three-
point scales used for severity, and six-point scales used for
caregiver distress. When a symptom is not present, the
frequency, severity, and caregiver distress are not scored
[51]. We plan to use the Dutch version of the NPI-NH,
which has demonstrated high inter-rater agreement and
validity as a rating scale [52].
The CMAI is the most used tool for determining the
frequency of agitation and aggression [53]. The CMAI
consists of 29 items, subdivided into three subscales:
physical aggression, physically nonaggressive behavior,
and verbally agitated behavior. Scores are rated on
seven-point Likert-type scales, rating symptoms over the
preceding 2 weeks from “never” to “several times an
hour” [54]. The translated and validated Dutch version
by De Jonghe and Kat (1996) will be used, which has
established reliability (Cronbach’s α = 0.82) and con-
struct validity (Inter-rater agreement = 0.89) [55–57].
The EQ-VAS records a respondent’s self-rated health
on a vertical scale ranging from “best imaginable health
state” to “worst imaginable health state” [58]. In our
study, we will use the two proxy-versions of the EQ-
VAS reported in a previous Dutch study [59]. Nursing
staff and family members will be asked to rate the resi-
dents’ QoL and health status, both from their own per-
spective and from the perspective of the resident. In
addition, the social engagement of residents will be mea-
sured as an important proxy of QoL, using the Revised
Index of Social Engagement (RISE) [60]. The RISE is
part of the inter-RAI Long-Term Care Facilities Assess-
ment System and consists of six dichotomous items re-
lated to social behavior [61–63]. Its reported reliability
and validity are considered sufficient [60].
Measurements problem assessment
We will gather information on inappropriate psycho-
tropic drug prescribing, frequency of psychotropic drug
use, NPS frequency, and QoL. Also, we will analyze
current difficulties in managing NPS using a self-
designed, digital questionnaire for NH staff (i.e., physi-
cians, psychologists, and nurses) to assess the following:
(1) the detection, analysis, treatment, and evaluation of
NPS, and (2), efforts to prevent NPS, any views about
NPS, and the presence of multidisciplinary cooperation.
The questionnaire will not be used to measure an out-
come; instead, it will only be used to examine problems
that NH staff perceive when dealing with NPS and in-
appropriate psychotropic drug prescribing. Scores will
be rated on four-point Likert-type scales ranging from
“never/rarely” to “at all times” for the frequency meas-
ure, and from “not satisfied” to “very satisfied” for the
extent of satisfaction. The questionnaire has been piloted
in two NHs and adjusted based on user experiences.
To gain a more in-depth insight into the processes
that play a role in managing NPS and the prescription of
psychotropic drugs, researchers (CGK, CvT) will con-
duct several semi-structured interviews with members of
the MPT (e.g., physicians, psychologists, nursing staff,
and managers). Several interviews were trialed in a pilot
study at two NHs, and the interview formats have been
adjusted according to user experience.
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We also plan to address the attitudes of health care
staff toward the use of new interventions or treatments.
Values and beliefs on these issues influence the degree
to which innovations are initiated and implemented in
clinical practice [64–66], and considering the attitudes
of professionals toward adopting new interventions can
facilitate implementation [67]. Therefore, we will admin-
ister the Evidence-Based Practice Attitude Scale (EBPAS)
developed by Aarons in 2004. This scale consists of four
subscales for 15 items that are measured on five-point
Likert scales, ranging from 0 (not at all) to 4 (to a very
great extent). The EBPAS assesses the extent to which a
professional (1) finds the intervention intuitively appeal-
ing, (2) would adopt an intervention if required by a
supervisor, (3) has a general openness to trying new in-
terventions, and (4) perceives interventions as being of
limited clinical value and less important than clinical ex-
perience. We will use the Dutch version, for which the
factor structure and reliability are comparable to the ori-
ginal version [68].
Furthermore, the organizational culture of the DSCUs
will be assessed using a Competing Values Framework
(CVF) scale [69]. This involves a questionnaire that con-
sists of 24 items on four-point Likert-type scales, ranging
from 1 (not characteristic) to 4 (very characteristic). It
aims to provide insight into the cooperation between
staff members and the working conditions and charac-
teristics of the DSCU, and it suggests either a dominant
culture type, a market type, an adhocracy type, or a hier-
archy culture type. We will use a Dutch version of the
questionnaire [70].
Both the EBPAS and the CVF scale will also be admin-
istered in the process evaluation, and they will be sent
digitally to NH staff. Finally, a self-designed paper and
pencil questionnaire will be used to assess the opinion of
family members regarding the delivered care and degree
of communication received with respect to NPS and/or
psychotropic drug use.
Sample size
For our primary outcome, we aim to detect a reduction
in inappropriate psychotropic drug prescribing of 5
points minimum (standard deviation = 15) on the APID
index from the baseline to the final measurement (16
months) [23, 71]. We expect that APID values will be
nested within NHs, the main level of randomization in
our design. Assuming an average size of 25 residents per
NH, a power of 0.80, a significance level (alpha) of 0.05,
we will need 284 psychotropic drug users. Given the
multilevel design with two measurements after baseline,
we anticipate that we will then need to increase this to a
sample size of 364 (15 clusters) for an intraclass correl-
ation coefficient of 0.1 [44] and a calculated design fac-
tor of 1.28 (the factor at which the original N has to
multiplied). To allow for a cluster dropout of about 10%
[72], and to obtain an even number of clusters, we plan
to include 16 clusters with 364 residents in total. Given
that approximately 60% of residents with dementia will
be prescribed psychotropic drugs [20], this number will
need to be further increased to 607 residents. Previous
studies have shown that we can also anticipate a loss to
follow-up of about 30% per year [5], which would
amount to 40% in the 16months in our study. However,
in the event a resident dies or moves away from the unit,
we will enroll the newly admitted resident, precluding
the need to account further for attrition. Consequently,
the case mix during our study will vary, and information
from dropouts will need to be included in an intention
to treat analysis.
Data analysis
Primarily, we will examine results between both arms;
the intervention group and the control group. Secondar-
ily, we will examine results between the short interven-
tion duration (8 months) and the long intervention
duration (16 months). All data will be entered in a se-
cured digital data management program. After collec-
tion, the data will be checked for outliers and extracted
into a statistical software package. Descriptive statistics
will be used to compare the baseline data between
groups. A multilevel model will then be used to study
the effects of a tailored intervention and implementation
plan on reducing inappropriate psychotropic drug pre-
scribing, based on the methods described by Twisk [73].
This model will be used for both the primary and sec-
ondary outcomes to account for the dependency of in-
formation due to the repeated measurements and cluster
randomization. A restricted iterative generalized least
squares algorithm will be used to estimate the regression
coefficients, and the Wald test will be used to obtain a P
value for each regression coefficient. Models will include
a fixed and a random intercept.
Analyses will be adjusted for baseline outcome values
(e.g., inappropriate psychotropic drug prescribing and
NPS), time, and confounders (e.g., cognitive abilities, as
measured with the CPS, type of dementia, distress in
nurses due to NPS). We will adjust for factors that could
explain why an intervention did not succeed at the team
level (e.g., staff attitudes toward the use of new interven-
tions or treatments, as measured by the EBPAS, and the
cooperation between staff members, the working condi-
tions and characteristics of the DSCU, as measured by
the CVF scale). Possible interaction effects of the inter-
vention with time and with an NH will also be investi-
gated. Sensitivity analyses will be used to examine
differences between NHs with respect to extent of per-
formance, considering whether degree of implementa-
tion (such as more coaching) is associated with a greater
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reduction of inappropriate prescribing or whether atti-
tude serves as an effect modifier. When indicated, sub-
group analyses will be used to consider NHs that
implement their plans unsuccessfully and NHs that im-
plement their plans successfully. We will also conduct a
missing value analysis to evaluate whether missing data
are likely to be missing at random, and we will consider
replacement if appropriate. Normal probability plots and
plots of standardized residuals versus predicted values
will be inspected to assess whether the assumptions of
normality and homogeneity of variance are met. In the
event of noncompliance, data transformation will be
considered. The double ratings of QoL and health status,
as perceived by nursing staff and family members, will
be analyzed separately. Data from the process evaluation
interviews will be examined in the content analysis and
any barriers and facilitators will be analyzed according
to the Consolidated Framework For Implementation Re-
search [74].
Discussion
To the best of our knowledge, no study has used a PAR-
RCT design to examine the effect of a tailored interven-
tion and implementation plan on the reduction of in-
appropriate psychotropic drug prescribing for NH
residents with dementia. We consider the study design
to be a strength of this proposal because active participa-
tion of NH staff (those most involved in the care
process) is most likely to engender engagement and
intervention suitability in the long-term [41]. In addition,
the use of coaching should ensure that implementation
conditions are optimal by ensuring that close attention
is paid to the local NH context, including staff commit-
ment [40].
We anticipate that the results of our study will provide
evidence for the effectiveness of a tailored intervention
and implementation plan. Additionally, the results
should offer insights into the issues surrounding the im-
plementation of complex interventions in NHs, includ-
ing relevant barriers and facilitators, which can be
accounted for in future implementation processes. The
use of a stepped-wedge design offers several advantages,
such as the possibility of between- and within-group
analyses, increased study power, and of comparing long-
and short-term intervention durations [44]. Given that
the design also ensures that each NH receives the inter-
vention, unlike in a standard RCT with a regular control
group that does not receive the intervention, we also an-
ticipate that this will enhance motivation in the partici-
pating NHs [75].
A few limitations also warrant mention, such as NHs
not being randomly selected and participation being on
a voluntary basis, which could introduce selection bias.
NHs and researchers will also be aware of the condition
(deferred intervention or intervention), which might in-
crease the likelihood of bias. In our sample size calcula-
tion, we use an effect size of 5 points on a scale ranging
from 0 to 102.8. Although this was required to show a
significant effect in favor of the intervention group in an
earlier study, there is insufficient literature to determine
whether this is clinically relevant. The APID index mea-
sures the appropriateness of psychotropic drug use based
on medical records, and its “indication” and “evaluation”
items have low inter-rater agreement, largely due to bias
in medical record extraction. In addition, scoring the
APID index can be affected by the quality of reporting.
Suboptimal recordkeeping, such as not reporting an in-
dication, could influence the score. Keeping medical files
up to date is therefore essential for accurate judging of
the appropriateness of prescribing [23].
Other limitations include the difficulty inherent to
examining the effect of an implemented intervention.
In the tailored intervention and implementation plan
with coaching, we can only evaluate the PAR-RCT de-
sign as a whole to help local practice with current
knowledge tailored to specific needs. We will be un-
able to state whether an intervention in NH “A” (e.g.,
GRIP) was more or less effective than that in NH “B”
(e.g., medication review), because each NH will be at
liberty to choose its own interventions. At best, the
sensitivity analyses will be able to show whether the
degree of implementation (e.g., more coaching) was
associated with a greater reduction in inappropriate
psychotropic drug prescribing or whether attitudes
better serve as an effect modifier. Also, secondary out-
comes (e.g., NPS and QoL) will be measured based on
proxy reports by nursing staff, which may be less reli-
able than direct measures. To account for this, we will
use common observation scales for NPS (e.g., the NPI-
NH and CMAI). Reporting bias may also occur for the
QoL measures [75]. Therefore, to enhance the cred-
ibility of the results in these domains, only NH staff
who are frequently involved in the daily care of a given
resident will be asked to complete the questionnaires.
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